The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol
Abstract
Aggregation of p53 mutants can result in loss-of-function, gain-of-function, and dominant-negative effects that contribute to tumor growth. Revealing the mechanisms underlying mutation-enhanced p53 aggregation and dissecting how small molecule inhibitors prevent the conversion of p53 into aggregation-primed conformations are fundamentally important for the development of novel therapeutics for p53 aggregation-associated cancers. A recent experimental study shows that resveratrol (RSV) has an inhibitory effect on the aggregation of hot-spot R248Q mutant of the p53 core domain (p53C), while pterostilbene (PT) exhibits a relatively poor inhibitory efficacy. However, the conformational properties of the R248Q mutant leading to its enhanced aggregation propensity and the inhibitory mechanism of RSV against p53C aggregation are not well understood. Herein, we performed extensive all-atom molecular dynamics simulations on R248Q p53C in the absence and presence of RSV/PT, as well as wild-type (WT) p53C. Our simulations reveal that loop L3, where the mutation resides, remains compact in WT p53C, while it becomes extended in the R248Q mutant. The extension of loop L3 weakens the interactions between loop L3 and two crucial aggregation-prone regions (APRs) of p53C, leading to impaired interactions within the APRs and their structural destabilization as well as p53C. The destabilized APRs in the R248Q mutant are more exposed than in WT p53C, which is conducive to p53C aggregation. RSV has a higher preference to bind to R248Q p53C than PT. This binding not only stabilizes loop L3 of R248Q mutant to its WT-like conformation, preventing L3-extension-caused APRs' destabilization but also reduces APRs' solvent exposure, thereby inhibiting R248Q p53C aggregation. However, PT exhibits a lower hydrogen-bonding capability and a higher self-association propensity, which would lead to a reduced p53C binding and a weakened inhibitory effect on R248Q mutant aggregation. Our study provides mechanistic insights into the R248Q mutation-enhanced aggregation propensity and RSV's potent inhibition against R248Q p53C aggregation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The R248Q mutation was initially considered a DNA contact mutation, and extensive research has shown that it significantly reduces or abolishes DNA binding due to its role in contacting the minor groove of DNA.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [26]
In the citing paper
“Recent NMR and MD simulation studies have also revealed two key effects: disruption of DNA contact and structural destabilization 25-28.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
p53 in the DNA–Damage–Repair Process
Williams, A. B., & Schumacher, B. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026070 · Cited by 835
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
Hot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K.-B., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 221
Solution structure of p53 core domain: Structural basis for its instability
Cañadillas, J. M. P., Tidow, H., Freund, S. M. V., Rutherford, T. J., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510941103 · Cited by 174
Degtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78
Research works printed but not linked: 69
- 10.1016/j.cell.2017.08.028 · DOI · Paper page
- 10.1007/BF00690207 · DOI · Paper page
- 10.1038/s41573-022-00571-8 · DOI · Paper page
- 10.1016/j.tcb.2009.10.002 · DOI · Paper page
- 10.1002/humu.20495 · DOI · Paper page
- 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
- 10.1038/sj.onc.1203434 · DOI · Paper page
- 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
- 10.1038/nchembio.546 · DOI · Paper page
- 10.1016/j.ccell.2020.11.013 · DOI · Paper page
- 10.1038/s41467-021-23985-1 · DOI · Paper page
- 10.1021/acs.accounts.7b00473 · DOI
- 10.1074/jbc.M112.340638 · DOI · Paper page
- 10.1021/bi034218k · DOI · Paper page
- 10.1186/s40164-022-00317-7 · DOI · Paper page
- 10.4161/pri.27776 · DOI
- 10.1016/j.tibs.2014.04.001 · DOI · Paper page
- 10.1016/j.biocel.2010.10.017 · DOI · Paper page
- 10.1016/j.bbrc.2012.11.130 · DOI
- 10.1128/MCB.24.8.3536-3551.2004 · DOI · Paper page
- 10.1016/0092-8674(91)90384-B · DOI · Paper page
- 10.1016/j.isci.2020.100820 · DOI
- 10.1038/cdd.2017.105 · DOI
- 10.1073/pnas.1500262112 · DOI · Paper page
- 10.18632/oncotarget.25631 · DOI
- 10.1016/j.bpj.2022.10.013 · DOI
- 10.1038/cdd.2013.17 · DOI · Paper page
- 10.1038/cddis.2014.75 · DOI
- 10.1073/pnas.2015618118 · DOI
- 10.1073/pnas.1700308114 · DOI · Paper page
- 10.1038/35094077 · DOI · Paper page
- 10.1074/jbc.RA118.004671 · DOI
- 10.1021/acs.chemrev.0c01122 · DOI · Paper page
- 10.1016/j.jnutbio.2005.01.017 · DOI · Paper page
- 10.3390/molecules22061014 · DOI
- 10.1021/ja8097417 · DOI
- 10.1074/jbc.M110.133108 · DOI · Paper page
- 10.1016/j.bbapap.2017.02.014 · DOI
- 10.1093/nar/gky1314 · DOI
- 10.1038/ncomms2361 · DOI · Paper page
- 10.1021/acschembio.9b00748 · DOI · Paper page
- 10.1039/C9CP06671C · DOI
- 10.1039/D1CP03094A · DOI · Paper page
- 10.1042/BCJ20190778 · DOI
- 10.1021/acs.jpcb.6b07457 · DOI
- 10.1021/acs.jcim.2c00380 · DOI
- 10.1016/j.celrep.2022.110622 · DOI · Paper page
- 10.1016/j.chembiol.2022.07.003 · DOI
- 10.1039/D1CP05670K · DOI
- 10.1016/j.jmb.2021.167048 · DOI
- 10.1038/s41467-021-21258-5 · DOI
- 10.1016/j.bpj.2022.03.030 · DOI
- 10.1158/1535-7163.MCT-22-0008 · DOI
- 10.1021/acs.jpcb.1c05638 · DOI
- Information. N. C. f. B. PubChem. Compound Summary for CID 445154, Resveratrol. https://pubchem.ncbi.nlm.nih.gov/compound/Resveratrol (accessed).
- Information. N. C. f. B. PubChem. Compound Summary for CID 5281727, Pterostilbene. https://pubchem.ncbi.nlm.nih.gov/compound/Pterostilbene (accessed).
- 10.1016/j.softx.2015.06.001 · DOI · Paper page
- 10.1038/nmeth.4067 · DOI · Paper page
- 10.1063/1.445869 · DOI · Paper page
- 10.1002/jcc.20290 · DOI · Paper page
- 10.1002/jcc.20035 · DOI · Paper page
- 10.1063/1.2408420 · DOI · Paper page
- 10.1080/00268978300102851 · DOI · Paper page
- 10.1063/1.464397 · DOI · Paper page
- 10.1002/bip.360221211 · DOI · Paper page
- 10.1126/science.3892686 · DOI · Paper page
- 10.1096/fj.01-0442hyp · DOI · Paper page
- 10.1074/jbc.RA118.003285 · DOI
- 10.1073/pnas.1211550109 · DOI · Paper page
Cited by
Bian, S., Bian, H., Koyama, H., Kompaniiets, D., Tse, W., Shah, M. V., Al-Kali, A., Miron, A., Liu, B., & Liu, S. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.131687
Metadata
- Authors
- Liu, Q., Li, L., Yu, Y., & Wei, G.
- Affiliations
- Department of Physics, State Key Laboratory of Surface Physics, and Key Laboratory for Computational Physical Sciences (Ministry of Education), Fudan University, Shanghai 200438, People’s Republic of China
- ORCID
- Wei, Guanghong
- Venue
- The Journal of Physical Chemistry B
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-09-04
- Volume
- 127
- Issue
- 36
- Pages
- 7708-7720
- ISSN
- 1520-6106
- 1520-5207
- Cited by
- 11
- References
- 10
- Language
- en
- Licence
- Funders
- Natural Science Foundation of Shanghai (22ZR1406800)
- National Natural Science Foundation of China (12074079)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.